Ovid Therapeutics Inc. (OVID): Price and Financial Metrics


Ovid Therapeutics Inc. (OVID): $3.76

-0.04 (-1.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OVID to Watchlist
Sign Up

Industry: Biotech


Ranked

of 498

in industry

OVID POWR Grades


  • Value is the dimension where OVID ranks best; there it ranks ahead of 99.98% of US stocks.
  • OVID's strongest trending metric is Growth; it's been moving up over the last 31 weeks.
  • OVID ranks lowest in Momentum; there it ranks in the 5th percentile.

OVID Stock Summary

  • With a price/earnings ratio of 2.24, Ovid Therapeutics Inc P/E ratio is greater than that of about only 1.06% of stocks in our set with positive earnings.
  • The ratio of debt to operating expenses for Ovid Therapeutics Inc is higher than it is for about just 0.53% of US stocks.
  • As for revenue growth, note that OVID's revenue has grown 3,096.4% over the past 12 months; that beats the revenue growth of 99.54% of US companies in our set.
  • Stocks that are quantitatively similar to OVID, based on their financial statements, market capitalization, and price volatility, are ITCI, CHMA, FULC, GMBL, and FIXX.
  • Visit OVID's SEC page to see the company's official filings. To visit the company's web site, go to www.ovidrx.com.

OVID Valuation Summary

  • In comparison to the median Healthcare stock, OVID's price/sales ratio is 90.72% lower, now standing at 1.1.
  • Over the past 51 months, OVID's EV/EBIT ratio has gone up 11.3.
  • Over the past 51 months, OVID's price/earnings ratio has gone up 15.6.

Below are key valuation metrics over time for OVID.

Stock Date P/S P/B P/E EV/EBIT
OVID 2020-03-20 NA 1.8 -2.1 -1.4
OVID 2019-02-25 NA 1.0 -1.0 -0.3
OVID 2018-05-14 NA 3.1 -5.0 -4.4
OVID 2017-08-17 NA 1.5 -7.0 -2.2
OVID 2017-07-21 NA 5.3 -10.0 -8.0
OVID 2017-07-10 NA 5.2 -9.9 -7.9

OVID Price Target

For more insight on analysts targets of OVID, see our OVID price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.88 Average Broker Recommendation 1.64 (Moderate Buy)

OVID Stock Price Chart Interactive Chart >

Price chart for OVID

OVID Price/Volume Stats

Current price $3.76 52-week high $4.80
Prev. close $3.80 52-week low $2.25
Day low $3.74 Volume 244,200
Day high $3.94 Avg. volume 2,229,329
50-day MA $4.07 Dividend yield N/A
200-day MA $3.40 Market Cap 254.95M

Ovid Therapeutics Inc. (OVID) Company Bio


Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York.


OVID Latest News Stream


Event/Time News Detail
Loading, please wait...

OVID Latest Social Stream


Loading social stream, please wait...

View Full OVID Social Stream

Latest OVID News From Around the Web

Below are the latest news stories about Ovid Therapeutics Inc that investors may wish to consider to help them evaluate OVID as an investment opportunity.

Ovid Therapeutics Strengthens Board & Leadership Team to Focus Efforts on Expanding Its Neurosciences Capabilities

Dr. Michael Poole to Join the Board of Directors Dr. Claude Nicaise Appointed Head of R&D and Jason Tardio Appointed Chief Operating Officer Dr. Amit Rakhit to Join the Scientific and Clinical Advisory Board NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) today announced appointments to its board of directors and leadership team as well as a realignment of its workforce to focus on early-stage development activities, including the build out of its neuroscience p

Yahoo | July 8, 2021

Ovid Therapeutics to Present at the Ladenburg Thalmann 2021 Healthcare Conference

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that management will present in a virtual format at the Ladenburg Thalmann 2021 Healthcare Conference on Wednesday, July 14, 2021 at 9:30 a.m. ET. A live webcast of the virtual presentation can be accessed through the Events & Presentations section of the Company’s websi

Yahoo | July 7, 2021

Should Weakness in Ovid Therapeutics Inc.'s (NASDAQ:OVID) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

It is hard to get excited after looking at Ovid Therapeutics' (NASDAQ:OVID) recent performance, when its stock has...

Yahoo | July 6, 2021

Ovid Therapeutics Appoints Jeff Rona as Chief Business and Financial Officer

– Broadened role enables deeper focus on the Company’s business strategy –NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that current Chief Business Officer Jeffrey Rona has expanded his role to include Chief Financial Officer responsibilities. “Ovid is moving forward with a very focused corporate strategy. Combining

Yahoo | June 4, 2021

Ovid Therapeutics Appoints Dr. Joy A. Cavagnaro and Dr. Bruce A. Sullenger to its Scientific Advisory Board

New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D. to its Scientific Advisory Board. “Ovid is building the intellectual and scientific platform to tackle the big questions in neuroscience so as to develop new medicines. To that end, Ovid is deepening the expertise and strengths of our Scientific Advisory Board by the addition of key leaders in specific areas. Accordingly, I am delighted to welcome Dr. Cavagnaro and Dr. Sullenger to the SAB,” said Professor Robert S. ...

Yahoo | May 26, 2021

Read More 'OVID' Stories Here

OVID Price Returns

1-mo -3.84%
3-mo 2.45%
6-mo 33.81%
1-year 13.94%
3-year -24.65%
5-year N/A
YTD 62.77%
2020 11.33%
2019 71.49%
2018 -75.48%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7503 seconds.